Shares of Novo Nordisk, the Danish pharmaceutical company behind weight-loss drugs Ozempic and Wegovy, plummeted this week.

The results Lilly is reporting for its oral pill come as another big drug company, Pfizer, has decided to discontinue its ...

By making the expected blockbuster pill in the U.S., Lilly may be able to avoid the impact of Trump’s sweeping tariffs, ...

Eli Lilly said in February that it will invest at least $27 billion to build four new manufacturing sites in the U.S. as ...

Eli Lilly & Co.'s stock soared 14% Thursday, to put it on track for its biggest one-day gain in about 25 years, after the drugmaker reported positive results from a late-stage trial of a GLP-1 ...

Shares of Eli Lilly (LLY) jumped on Thursday morning after the company announced topline Phase 3 results from ACHIEVE-1, evaluating the safety and efficacy of orforglipron compared to placebo in ...

A new drug, called orforglipron, can help people with diabetes manage their A1C and weight, according to topline results from ...

Following the company’s announcement that its diabetes and weight-loss drug helped patients lose up to 16 pounds over 40 ...

According to an official statement from Eli Lilly and Company, "Orforglipron is the first oral small-molecule glucagon-like peptide-1 (GLP-1) receptor agonist, taken without food and water ...

The company plans to seek regulatory approval for the revolutionary weight loss treatment by the end of the year.

A new daily pill that suppresses the appetite has been shown to help patients lose weight in clinical trials.

Eli Lilly's new oral weight loss pill, orforglipron, shows promise in Phase 3 trials, offering a convenient alternative to ...